Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the european prospective investigation into cancer and nutrition

American Journal of Epidemiology

Volumn 172, Issue 12, 2010, Pages 1394-1403

  Allen, Naomi E ^a   Tsilidis, Konstantinos K ^a   Key, Timothy J ^a   Dossus, Laure ^a   Kaaks, Rudolf ^a   Lund, Eiliv ^a   Bakken, Kjersti ^a   Gavrilyuk, Oxana ^a   Overvad, Kim ^a   Tjønneland, Anne ^a   Olsen, Anja ^a   Fournier, Agnès ^a   Fabre, Alban ^a   Francxoise, Clavel Chapelon ^a   Nathalie, Chabbert Buffet ^a   Sacerdote, Carlotta ^a   Krogh, Vittorio ^a   Bendinelli, Benedetta ^a   Tumino, Rosario ^a   Panico, Salvatore ^a   Bergmann, Manuela ^a   Schuetze, Madlen ^a   Duijnhoven, Fränzel J B Van ^a   Bas, H Bueno De Mesquita ^a   Charlotte, N Onland Moret ^a   Gils, Carla H Van ^a   Amiano, Pilar ^a   Barricarte, Aurelio ^a   Chirlaque, Maria Dolores ^a   Molina Montes, Maria Esther ^a   Redondo, María Luisa ^a   Duell, Eric J ^a   Khaw, Kay Tee ^a   Wareham, Nick ^a   Rinaldi, Sabina ^a   Fedirko, Veronika ^a   Mouw, Traci ^a   Michaud, Dominique S ^a   Riboli, Elio ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Endometrial neoplasms; Estrogen replacement therapy; Norpregnenes; Postmenopause; Prospective studies

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; TESTOSTERONE DERIVATIVE; TIBOLONE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGE CLASS; CANCER; COHORT ANALYSIS; HEALTH RISK; HORMONE; NUTRITION; REGRESSION ANALYSIS; REPRODUCTIVE BIOLOGY; RISK FACTOR; SMOKING; TUMOR; WOMENS HEALTH;

ADULT; CANCER RISK; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NUTRITION; POSTMENOPAUSE; REVIEW; SMOKING; AGE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; ENDOMETRIUM TUMOR; ESTROGEN THERAPY; EUROPE; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

AGE FACTORS; AGED; BODY MASS INDEX; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79952115034     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq300     Document Type: Review

References (40)

1. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol. 1995;85(2):304-313
2. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131-1137
3. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57(2):205-212
4. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1739-1748
5. Beral V, Bull D, Reeves G. Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543-1551
6. Hill DA,Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000;183(6):1456-1461
7. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89(15):1110-1116
8. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B): 1113-1124
9. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771
10. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010. Oslo, Norway: Norwegian Institute of Public Health; 2010. (http://www.whocc.no/atc-ddd-index/). (Accesssed March 2, 2010)
11. Stanczyk FZ. All progestins are not created equal. Steroids. 2003;68(10-13):879-890
12. Wareham NJ, Jakes RW, Rennie KL, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407-413
13. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241
14. Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. 2004(3):CD000402. (doi: 10.1002/14651858.CD000402.pub2)
15. Beresford SA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997;349(9050):458-461
16. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Longterm use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol. 2007;197(2):139.e1-139.e7
17. Reed SD, Voigt LF, Beresford SA, et al. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2004;191(4):1146-1151
18. Karageorgi S, Hankinson SE, Kraft P, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer. 2010;126(1):208-216
19. Razavi P, Pike MC, Horn-Ross PL, et al. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(2):475-483
20. Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control. 2003;14(2): 195-201
21. Lacey JV Jr, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer. 2007;109(7):1303-1311
22. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298(6667):147-151
23. Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol. 2006;164(8):775-786
24. Epstein E, Lindqvist PG, Olsson H. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. Int J Cancer. 2009;125(2):421-425
25. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58-66
26. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol. 2000;53(4):385-391
27. Lacey JV Jr, Brinton LA, Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14(7): 1724-1731
28. Wood CE, Sitruk-Ware RL, Tsong YY, et al. Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model. Menopause. 2007;14(4):639-647
29. Jondet M, Maroni M, Yaneva H, et al. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas. 2002;41(2):115-121
30. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111
31. de Vries CS, Bromley SE, Thomas H, et al. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Saf. 2005;28(3):241-249
32. Wierik EJ, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. Climacteric. 2004;7(2):197-209
33. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993;81(2): 265-271
34. Rubin GL, Peterson HB, Lee NC, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990;162(1):148-154
35. Shields TS, Weiss NS, Voigt LF, et al. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Epidemiology. 1999;10(6): 733-738
36. Newcomer LM, Newcomb PA, Trentham-Dietz A, et al. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control. 2001;12(9):829-835
37. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333
38. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427
39. Faber A, Bouvy ML, Loskamp L, et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a followup study. Br J Clin Pharmacol. 2005;60(6):641-647
40. Watson J,Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol. 2007;63(9):843-849